Literature DB >> 1814846

Prothymosin alpha enhances interleukin 2 receptor expression in normal human T-lymphocytes.

O J Cordero1, C S Sarandeses, J L López, E Cancio, B J Regueiro, M Nogueira.   

Abstract

We investigated whether the enhancement, by prothymosin alpha (Pro alpha), of the phytohaemagglutinin-stimulated proliferation of human peripheral blood mononuclear cells (PBMC) is due to its affect on the number of cells expressing the interleukin 2 receptor (IL-2R) or the surface density of IL-2R on PBMC. Peripheral blood mononuclear cells were obtained from 21 donors. For both an optimal phytohaemagglutinin (PHA) concentration (H) and a 10-fold dilution (L), their responses fell in two classes, high (h) and low (l), making four dose--response situations. Pro alpha significantly increased the number and IL-2R density of cells expressing IL-2R only when the response in its absence was about half maximal, i.e. for PBMC responding well to the low PHA stimulus (group Lh) or PBMC responding poorly to the optimal stimulus (group Hl). The enhancement of IL-2R expression in group Lh by Pro alpha was dose-dependent and paralleled by increased proliferative response. It appears not to be mediated by IL-2, since it was unaffected when IL-2 production was suppressed by cyclosporin A. The early interaction of Pro alpha with lymphocytes did not require the presence of macrophages, but macrophages were necessary during lymphocyte activation for modulation of PHA-stimulated IL-2R expression to be affected. The immunoregulatory activity of Pro alpha may prove useful for improving the decreased T-cell function associated with immunodeficiency, or for restoration of normal IL-2R expression by the lymphocytes of aged individuals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1814846     DOI: 10.1016/0192-0561(91)90156-2

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  6 in total

Review 1.  Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker.

Authors:  Anastasios I Birmpilis; Antonios Paschalis; Apostolis Mourkakis; Panayiota Christodoulou; Ioannis V Kostopoulos; Elina Antimissari; Georgia Terzoudi; Alexandros G Georgakilas; Christina Armpilia; Panagiotis Papageorgis; Efstathios Kastritis; Evangelos Terpos; Meletios A Dimopoulos; Hubert Kalbacher; Evangelia Livaniou; Maria-Ioanna Christodoulou; Ourania E Tsitsilonis
Journal:  Cells       Date:  2022-04-22       Impact factor: 7.666

2.  Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer.

Authors:  Yuh-Shyan Tsai; Yeong-Chin Jou; Chun-Liang Tung; Chang-Te Lin; Cheng-Huang Shen; Syue-Yi Chen; Hsin-Tzu Tsai; Chen-Li Lai; Chao-Liang Wu; Tzong-Shin Tzai
Journal:  Virchows Arch       Date:  2014-04-15       Impact factor: 4.064

3.  Adenovirus-mediated prothymosin α gene transfer inhibits the development of atherosclerosis in ApoE-deficient mice.

Authors:  Meng-Ya Chang; Yu-Shan Yang; Mei-Ling Tsai; Che-Hsin Lee; Chih-Jui Chang; Ai-Li Shiau; Chao-Liang Wu
Journal:  Int J Biol Sci       Date:  2014-03-15       Impact factor: 6.580

4.  Prothymosin-α enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer.

Authors:  Yuh-Shyan Tsai; Yeong-Chin Jou; Hsin-Tzu Tsai; Ai-Li Shiau; Chao-Liang Wu; Tzong-Shin Tzai
Journal:  Cancer Sci       Date:  2019-03-05       Impact factor: 6.716

Review 5.  Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Authors:  P Samara; K Ioannou; O E Tsitsilonis
Journal:  Vitam Horm       Date:  2016-05-27       Impact factor: 3.421

6.  Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.

Authors:  Anastasios I Birmpilis; Chrysoula-Evangelia Karachaliou; Pinelopi Samara; Kyriaki Ioannou; Platon Selemenakis; Ioannis V Kostopoulos; Nadia Kavrochorianou; Hubert Kalbacher; Evangelia Livaniou; Sylva Haralambous; Athanasios Kotsinas; Farzin Farzaneh; Ioannis P Trougakos; Wolfgang Voelter; Meletios-Athanasios Dimopoulos; Aristotelis Bamias; Ourania Tsitsilonis
Journal:  Cancers (Basel)       Date:  2019-11-09       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.